White R, Woolf D, Li S, Alonzi R, Osler P, Hoskin P, Hughes R
Department of Clinical Oncology, Mount Vernon Cancer Centre, Northwood, United Kingdom.
Indian J Cancer. 2015 Oct-Dec;52(4):654-7. doi: 10.4103/0019-509X.178409.
Hypofractionated radiotherapy in the radical treatment of localized prostate cancer has potential biological advantages relative to conventional fractionation. We report prospectively collected toxicity data from a cohort of patients treated with a 3D conformal technique (3DCRT).
90 patients receiving curative intent hypofractionated radiotherapy with 57Gy in 19 daily fractions over 3.8 weeks were evaluated prospectively for the development of radiation related toxicity over a 3 year period.
All patients completed treatment. Maximal acute toxicity experienced was 58.6, 10 and 1.1% for grade 1, 2 and 3 genitourinary (GU) toxicity respectively and 75.6, 9 and 0% for gastrointestinal (GI) toxicity. For late toxicity the three year actuarial rates of grade 1, 2 and 3 GU and GI toxicity respectively were 47.3, 2.4 and 0%; and 40, 9.3 and 4.7%. There were no grade 4 or worse acute or late toxicities. 97.6% of evaluable patients remained free of biochemical failure 36 months post radiotherapy.
A 57Gy in 19 daily fraction radiotherapy schedule using 3D conformal radiotherapy for the definitive treatment of localized prostate cancer has acceptable early and late toxicity.
与传统分割放疗相比，大分割放疗在局限性前列腺癌的根治性治疗中具有潜在的生物学优势。我们前瞻性地报告了一组采用三维适形技术（3DCRT）治疗的患者的毒性数据。
对90例接受根治性大分割放疗的患者进行了前瞻性评估，这些患者在3.8周内分19次给予57Gy剂量，观察其在3年内放射性毒性的发生情况。
所有患者均完成治疗。1、2、3级泌尿生殖系统（GU）急性毒性发生率分别为58.6%、10%和1.1%，胃肠道（GI）急性毒性发生率分别为75.6%、9%和0%。对于晚期毒性，1、2、3级GU和GI毒性的3年精算发生率分别为47.3%、2.4%和0%；以及40%、9.3%和4.7%。没有4级或更严重的急性或晚期毒性。97.6%的可评估患者在放疗后36个月无生化复发。
采用三维适形放疗对局限性前列腺癌进行根治性治疗，19次分割给予57Gy的放疗方案具有可接受的早期和晚期毒性。
